← Back to Search

Educational Intervention for Alzheimer's Disease (D-PRESCRIBE-AD Trial)

N/A

Waitlist Available

Led By Jerry H Gurwitz, MD

Research Sponsored by University of Massachusetts, Worcester

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥50 years of age as of cohort entry date

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 9 months

Awards & highlights

D-PRESCRIBE-AD Trial Summary

This trial will test whether an educational intervention can reduce potentially inappropriate prescribing in patients with Alzheimer's disease or related dementias.

Who is the study for?

This trial is for adults aged 50 or older with Alzheimer's Disease or related dementias who have been taking certain medications that might not be needed anymore. They should have had continuous health coverage for the past year and evidence of potentially inappropriate prescriptions within the last three months.Check my eligibility

What is being tested?

The study tests an educational program aimed at reducing unnecessary medication use among patients with Alzheimer's by improving communication between them, their caregivers, and healthcare providers. It compares this approach to usual care in a randomized controlled setting.See study design

What are the potential side effects?

Since the intervention involves educational materials rather than drugs, there are no direct side effects from medications being tested. However, changes in medication regimens as a result of education could lead to withdrawal symptoms or other effects.

D-PRESCRIBE-AD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 50 years old or older.

D-PRESCRIBE-AD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 9 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~9 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Absence of Inappropriate Medication Prescription Dispensing

Secondary outcome measures

Dose Change

Mortality

Polypharmacy

+2 more

D-PRESCRIBE-AD Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Provider OnlyExperimental Treatment1 Intervention

Only providers will receive educational materials on inappropriate prescribing and deprescribing.

Group II: Patient-ProviderExperimental Treatment1 Intervention

Both patients and providers will receive educational materials on inappropriate prescribing and deprescribing.

Group III: Usual CareActive Control1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Anthem, IncIndustry Sponsor

1 Previous Clinical Trials

901 Total Patients Enrolled

University of Massachusetts, WorcesterLead Sponsor

342 Previous Clinical Trials

962,168 Total Patients Enrolled

Harvard Pilgrim Health CareOTHER

54 Previous Clinical Trials

27,766,536 Total Patients Enrolled

Media Library

Educational Materials Clinical Trial Eligibility Overview. Trial Name: NCT05147428 — N/A

Alzheimer's Disease Research Study Groups: Usual Care, Patient-Provider, Provider Only

Alzheimer's Disease Clinical Trial 2023: Educational Materials Highlights & Side Effects. Trial Name: NCT05147428 — N/A

Educational Materials 2023 Treatment Timeline for Medical Study. Trial Name: NCT05147428 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is the recruitment for this investigation being pursued?

"Indeed, the information on clinicaltrials.gov reveals that this trial is currently recruiting. This medical experiment was initially posted on June 21st 2022 and has been recently modified as of August 15th 2022. The study needs to enrol fifteen thousand participants from a single location."

Answered by AI

Are participants currently being recruited for this medical experiment?

"Affirmative. According to the information uploaded on clinicaltrials.gov, this healthcare study is currently recruiting participants; it was initially made public on June 21st 2022 and its latest update occurred on August 15th 2022. The trial seeks to enrol a total of 15000 people at a single location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease

Jerry Gurwitz 2022. "A Program to Reduce Inappropriate Medications Among Older Adults With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05147428.